Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Director Bruce L. A. Carter sold 1,546 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $99.16, for a total transaction of $153,301.36. Following the transaction, the director now owns 1,546 shares of the company’s stock, valued at $153,301.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Enanta Pharmaceuticals stock opened at $102.85 on Friday. Enanta Pharmaceuticals Inc has a twelve month low of $64.08 and a twelve month high of $127.77. The firm has a market capitalization of $1.99 billion, a P/E ratio of 29.55 and a beta of 1.39.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.21). Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. The business had revenue of $69.89 million during the quarter, compared to the consensus estimate of $71.27 million. During the same period in the prior year, the firm earned $0.59 EPS. The business’s revenue for the quarter was up 83.4% compared to the same quarter last year. On average, analysts forecast that Enanta Pharmaceuticals Inc will post 1.51 EPS for the current year.
Several institutional investors have recently modified their holdings of ENTA. Vanguard Group Inc boosted its position in Enanta Pharmaceuticals by 30.1% during the third quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after acquiring an additional 330,374 shares during the last quarter. Vanguard Group Inc. boosted its position in Enanta Pharmaceuticals by 30.1% during the third quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after acquiring an additional 330,374 shares during the last quarter. Matarin Capital Management LLC bought a new stake in Enanta Pharmaceuticals during the third quarter valued at $17,964,000. BlackRock Inc. boosted its position in Enanta Pharmaceuticals by 6.5% during the third quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock valued at $221,354,000 after acquiring an additional 157,166 shares during the last quarter. Finally, Norges Bank bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at $7,106,000. 86.20% of the stock is currently owned by institutional investors.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
See Also: Gross Domestic Product (GDP)
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.